YS247

YS247 is an investigational autologous dendritic cell (DC) vaccine developed by Peking University Third Hospital for the treatment of epithelial ovarian cancer, specifically targeting patients with homologous recombination deficiency (HRD)-negative disease. The therapy is a personalized immunotherapy that involves harvesting a patient's own dendritic cells and pulsing or sensitizing them with tumor-specific neoantigens identified from the patient's individual tumor profile. These sensitized dendritic cells are then re-injected into the patient to function as professional antigen-presenting cells, which prime and activate the immune system—particularly cytotoxic T lymphocytes—to recognize and attack tumor cells expressing those unique neoantigens. This approach is designed to enhance the anti-tumor immune response in cancers that have failed standard first-line therapies.

Other names

Tumor Neoantigen-Sensitized Autologous Dendritic Cell InjectionTumor Neoantigen-pulsed Autologous Dendritic Cell Injection